Bibliographic Info
GuidelineWHO Guidelines for malaria, 14 March 2023
Year of Publication2023
Issuing InstitutionWHO
Recommendation
Status
Maintained
Recommended in favor
Strong
Certainty of evidence
Very low
Short-course standard dose primaquine treatment: To prevent relapse, an additional treatment option of using primaquine 0.5 mg/kg/day for seven days is recommended to treat P. vivax or P. ovale malaria in children and adults (except pregnant women, infants aged < 6 months, women breastfeeding infants aged < 6 months, women breastfeeding older infants unless they are known not to be G6PD deficient, and people with G6PD deficiency).
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
WHO guidelines for malaria, 25 November 2022.
Year2022
InstitutionWorld Health Organization